Stella Shi is a principal with Lilly Asia Ventures (LAV) with strong expertise in novel therapeutics. She sits on boards of multiple biotech startups in Asia and China, including Elpiscience Biopharmaceuticals, NextCure, InventisBio, Impact Therapeutics, FutureGen, etc. Before LAV, she was a disease area manager for oncology at Roche Pharmaceuticals Asia Pacific overseeing new product strategy in China and Asia. Previously, Stella worked with ZS Associates as a consultant. Stella holds a B.S. in molecular biology from Fudan University.